Multicentre assessment and monitored use of [18F]FDG-PET in oncology: The Spanish experience

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 2, 2008, Pages 296-304

  Rodríguez Garrido, Manuel ^a   Asensio Del Barrio, Cristina ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Diagnostic imaging; FDG; Health technology assessment; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CHILD; CLINICAL DECISION MAKING; CONFIDENCE INTERVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SPAIN;

EID: 38349088041     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0502-6     Document Type: Article

References (47)

1. Office of Technology Assessment. Assessing the efficacy and safety of medical technologies. Washington, DC.: U.S. Government Printing Office, September 1978. NTIS order #PB-286929.
2. Real Decreto 63/1995, de 20 de enero, sobre Ordenación de Prestaciones Sanitarias del Sistema Nacional de Salud. Boletín Oficial del Estado, no. 35, (10-2-1995).
3. Ley 16/2003, de 28 de mayo, de Cohesión y Calidad del Sistema Nacional de Salud. Boletín Oficial del Estado, no. 128, (29-05-2003).
4. Hawkins RA, Hoh CK. PET FDG studies in oncology. Nucl Med Biol 1994;21(5):739-47.
5. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006;354:496-507.
6. Kumar R, Nadig MR, Chauhan A. Positron emission tomography: clinical applications in oncology. Part 1. Expert Rev Anticancer Ther 2005;5:1079-94.
7. Van Heertum RL, Greenstein EA, Tikofsky RS. 2-Deoxy-fluorglucose-positron emission tomography imaging of the brain: current clinical applications with emphasis on the dementias. Semin Nucl Med 2004;34:300-12.
8. Wang J, Maurer L. Positron Emission Tomography: applications in drug discovery and drug development. Curr Top Med Chem 2005;5:1053-75.
9. Machac J. Cardiac positron emission tomography imaging. Semin Nucl Med 2005;35:17-36.
10. Delbeke D. Oncological applications of FDG-PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 1999;40:591-603.
11. Warburg O. On the metabolism of tumors in the body. In: Warburg O, editor. London: Constable and Co. 1930. p. 75-327.
12. Smith TA. FDG uptake, tumor characteristics and response to therapy: a review. Nucl Med Commun 1998;19:97-195.
13. 18F] 2-deoxy-2-fluoro-D- glucose. J Nucl Med 1978;19:1154-61.
14. Bury T, Dowlati A, Paulus P, Corhay JL, Benoit T, Kayembe JM, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Resp J 1996;9:410-4.
15. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996;37:943-8.
16. Mavi A, Lakhani P, Zhuang H, Gupta NC, Alavi A. Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiol Clin North Am 2005;43:1-21.
17. Chin R, Ward R, Keyes JW, Choplin RH, Reed JC, Wallenhaupt, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Resp and Crit Care Med 1995;152:2090-6.
18. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998;9(10):1117-22.
19. Boni R, Boni RA, Steinert H, Burg G. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D- glucose. Br J Dermatol 1995;132:556-562.
20. Stokkel MP, ten Broek FW, Hordijk GJ, Koole R, van Rijk PP. Preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emission tomography. Ann Surg 2000;231(2):229-34.
21. 18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85(3):1107-13.
22. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227(5):764-9.
23. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6(4):325-9.
24. 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003;44:1301-14.
25. Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004;101:2641-9.
26. Schiepers C, Penninckx F, De Vadder N, Mercks E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-22.
27. Lowe VJ, Boyd JH, Dunphy FR, Kim H, Dunleavy T, Collins BT, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000;18(3):651-8.
28. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26(12):1547-52.
29. Asensio C, Pérez-Castejón MJ, Maldonado A, Montz R, Ruiz JA, Santos M, et al. Papel de la FDG PET ante la duda diagnóstica de recidiva frente a necrosis en tumores cerebrales. Rev Neurol 1998;27(157):447-52.
30. Lowe VJ, Boyd JH, Dunphy FR, Kim H, Dunleavy T, Collins BT, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000;18(3):651-8.
31. Ito K, Kato T, Ohta T, Tadokoro M. Fluorine-18-fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity. Eur J Nucl Med 1996;23:1372-7.
32. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor form radiation necrosis: time for re-evaluation of positron emission tomography? Am J Neuroradiol 1998;19:407-13.
33. 131I-scintigraphy in the treatment and follow-up of thyroid cancer. Single-photon-emitters or FDG-PET? Q J Nucl Med 1999;43(3):195-206.
34. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18(8):1689-95.
35. Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med 2005;35:186-96.
36. Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology 2005;236:841-51.
37. 18F-fluorodeoxiglucosa). Documento de consenso. Agencia de Evaluación de Tecnologías Sanitarias (AETS), ISCIII. Madrid, mayo de 2001.
38. Rodríguez Garrido M, Conde Olasagasti M, González Enríquez J, Alcaide JF, Miguélez Hernández C. Informe sobre la tomografía por emisión de positrones con fluordeoxiglucosa (FDG-PET) en neurología. Ministerio de Sanidad y Consumo-Instituto de Salud Carlos III. Agencia de Evaluación de Tecnologías Sanitarias (AETS). Madrid, junio de 1999.
39. Rodríguez Garrido M, Conde Olasagasti JL, García Comas L, Alcaide JF. Informe sobre la tomografía por emisión de positrones (PET) en oncología clínica no neurológica. Ministerio de Sanidad y Consumo-Instituto de Salud Carlos III. Agencia de Evaluación de Tecnologías Sanitarias (AETS). Madrid, octubre de 1997.
40. Rodríguez Garrido M, Asensio del Barrio C, Gómez Martínez MV, Carreras Delgado JL, Martín Moreno JM. Tomografía por Emisión de Positrones (PET) con 18FDG en Oncología Clínica (Revisión Sistemática). Ministerio de Sanidad y Consumo. Instituto de Salud Carlos III. Agencia de Evaluación de Tecnologías Sanitarias (AETS). Madrid: AETS - Instituto de Salud Carlos III, noviembre de 2001.
41. 18F-fluordesoxyglucose. Rev Esp Med Nuclear 2002;21(2):128-30.
42. Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485-90.
43. Hospital Ramón y Cajal [sede Web]. Madrid: Hospital Ramón y Cajal; 2004 [acceso: 15 de mayo de 2004]. Unidad de investigación del Hospital Ramón y Cajal. Programa de meta-análisis de pruebas diagnósticas MetaDiSc. Disponible en: http://www.hrc.es/investigacion/ metadisc.html.
44. Ell PJ. The contribution of PET/CT to improved patient management. Br J Radiol 2006;79:32-6.
45. 18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg 2006;93:243-9.
46. Fanti S, Franchi R, Battista G, Monetti N, Cangini R. PET and PET-CT. State of the art and future prospects. Radiol Med 2005;110:1-15.
47. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Mak 1991;11:88-94.